Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

260
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
260

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting early bactericidal activity of tuberculosis drug combinations using a translational pharmacokinetic-pharmacodynamic modeling approach.

bioRxiv : the preprint server for biology·2026
Same author

A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse model.

Antimicrobial agents and chemotherapy·2026
Same author

A stochastic simulation-based approach to inform the relapsing mouse model study design for non-clinical assessment of tuberculosis.

Antimicrobial agents and chemotherapy·2025
Same author

The role of cytochrome bc<sub>1</sub> inhibitors in future tuberculosis treatment regimens.

Nature communications·2025
Same author

Erratum for Singh et al., "Repurposing drugs to advance the treatment of Buruli ulcer".

Antimicrobial agents and chemotherapy·2025
Same author

Strategies for shortening tuberculosis therapy.

Nature medicine·2025

Related Experiment Video

Updated: Oct 5, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.0K

Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens

Alexander Berg1, James Clary1, Debra Hanna2

  • 1Cognigen Corporation, a Division of Simulations Plus, Inc., Buffalo, New York, USA.

Antimicrobial Agents and Chemotherapy
|January 31, 2022
PubMed
Summary

Developing new tuberculosis (TB) treatments requires comparing drug regimens. A meta-analysis of mouse models provides a standardized method to compare TB drug efficacy, aiding selection for clinical trials.

Keywords:
Mycobacteriummodel-based meta-analysismodeling and simulationrelapsing mouse modeltuberculosis

More Related Videos

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally
05:40

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Published on: April 25, 2025

990
An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
09:02

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Published on: February 17, 2014

20.0K

Related Experiment Videos

Last Updated: Oct 5, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.0K
Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally
05:40

Preparation of Agar Bead Embedded Mycobacterium abscessus to Inoculate Immunocompetent Mice Intratracheally

Published on: April 25, 2025

990
An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei
09:02

An Experimental Model to Study Tuberculosis-Malaria Coinfection upon Natural Transmission of Mycobacterium tuberculosis and Plasmodium berghei

Published on: February 17, 2014

20.0K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Biostatistics

Background:

  • Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a major global health threat.
  • New TB treatment regimens are urgently needed.
  • The relapsing mouse model (RMM) is crucial for nonclinical evaluation of TB drug combinations.

Purpose of the Study:

  • To develop a standardized method for comparing TB drug regimen efficacy using RMM data.
  • To address challenges in comparing RMM study results due to inter-study variability.
  • To identify promising TB drug combinations for clinical development.

Main Methods:

  • A model-based meta-analysis was conducted on data from 28 RMM studies involving 1592 mice and 17 regimens.
  • A mixed-effects logistic regression model was developed to assess relapse probability over treatment duration.
  • Covariates influencing inter-study variability were identified and adjusted for.

Main Results:

  • The meta-analysis enabled covariate-normalized comparison of regimen performance.
  • Key metrics, such as treatment duration for 50% and 10% relapse probability, were derived.
  • The developed model facilitates the analysis of new RMM data alongside historical data.

Conclusions:

  • Model-based meta-analysis provides a robust framework for cross-study comparison of TB drug efficacy in RMMs.
  • This approach enhances the selection of candidate TB drug regimens for clinical evaluation.
  • Standardized comparison aids in the efficient development of improved TB treatments.